National centralized procurement of crown stent landing, benefit patients like!

Pharmaceutical Network January 8th, January 6th, CCTV "Asadontic World" again concerned about the national organization's crown vein stent centralized belt procurement results in Beijing, Tianjin, Liaoning and other 18 provinces and cities (regions) of the implementation of the landing, clinicians and patients have said that they can use cheap, excellent quality crown stent products, greatly reducing the medical burden.
state organization crown brace centralized belt procurement in early November 2020 produced the results of the election, 10 selected varieties, from the average price of 13,000 yuan to about 700 yuan, a decrease of more than 90%.
centralized medical institutions procurement quantity, in exchange for quantity to obtain the price reduction of pharmaceutical products, and thus regulate medical behavior, purify the industry environment, from January 1 this year, the official landing.
It is learned that the state organization of the crown vein bracket centralized procurement of the first batch of 18 provinces and cities (regions), including Beijing, Tianjin, Hebei, Liaoning, Jilin, Heilongjiang, Jiangsu, Zhejiang, Fujian, Shandong, Hunan, Guangdong, Hainan, Guizhou, Yunnan, Gansu, Qinghai, Xinjiang (including the Corps).
The first batch of 18 provinces and cities (districts) to land in the local inventory of selected products reached an average of 33% of the agreed procurement volume, to meet the first month of medical institutions to meet the demand for use;
in Huzhou, Zhejiang Province, 81-year-old Lu Meijiang recently came to Huzhou City Center Hospital for angina.
examination, doctors found that the Lumeijiang coronary artery is severely stenosis, two of the blood vessels have more than 95% blockage, very prone to acute heart attack, life-threatening.
the early hours of January 1, the hospital took catheter intervention surgery and implanted two coronary stents for the patient.
Lu Meijiang daughter Lu Jianxuan: these two brackets cheaper than 20,000 yuan, and then installed 2 balloons, cheaper than 8000 yuan, we calculate to see (cheap) more than 30,000 yuan.
Huzhou City Center Hospital Department of Internal Medicine Chief Physician Yan Haifeng: after the implementation of the new policy price, the new tender bracket, balloon material quality is the same as before, did not say that the price is much cheaper on the introduction of some different things, it is impossible, the country has quality control, there are indicators, things are the same.
In Xiangtan, Hunan Province, 76-year-old Xiang Donglin cross Chinese New Year's Eve sudden chest pain, fell to the ground, was rushed to Xiangtan City First People's Hospital, after chest pain center diagnosed as "acute myocardial infarction", January 1, 2021, medical staff for Donglin coronary stent surgery.
surgery, the old man's family was thrilled to learn that a stent was only 798 yuan.
to Donglin's daughter Zhang He cui: I am very grateful to the country for our farmers' concern and love, I am really happy to hear this news, because we work outside to earn a penny is really not easy.
to ensure that patients can use the selected products on January 1, 2021, Xiangtan City First People's Hospital has put the selection of stent procurement arrangements in place.
Xiangtan City First People's Hospital Vice President Wu Yongjun: Our hospital is also in accordance with the requirements of the document, in accordance with our annual surgical volume and stent use, reserve more than 20%, which can guarantee our patients, existing patients at least one month to ensure supply, from the price than the original significantly reduced, (national collection) quality is also very secure.
market concentrated on the promotion of bracket price reduction national collection crown vein bracket average decline of 93%, the mid-price of about 700 yuan.
, centralized bidding and procurement, reduce intermediate circulation links and other factors contributed to a significant reduction in product prices.
At present, from the market competition pattern, the total market share of the three domestic crown support enterprises reached 67%, the 10 selected varieties, domestic accounted for 7, domestic crown support quality has been market and clinical use of the two-step verification, enterprises in line with national reform measures, through price reduction to maintain their share, and further improve market share.
chen Jinfu, deputy director of the State Health Security Administration: Then centralized bidding and procurement, it should be said that the main purpose is to eliminate the gold sales here, through this market price exchange, volume price linkage, recruitment and collection to promote the new mechanism reconstruction in the field of recruitment.
through the market to find a reasonable mechanism to find the price to squeeze out the crown bracket gray price moisture, the most important squeeze is including the circulation of water, rather than at the expense of production processes, standard technology and quality.
A medical device enterprise in Suhua: We originally had hundreds of dealers, first- and second-level, agents at all levels in the country more, not us, the whole industry is like this, has been developed like this, but this time after the collection, in the final analysis is to make the industry more transparent, less intermediate links, I believe that after this collection, the vast majority of enterprises like us, basically manufacturers directly to the hospital.
As of December 30, 2020, the first batch of 18 provinces and urban areas to land in the local inventory of selected products has reached an average of 33% of the annual agreed procurement volume, reducing the intermediate circulation link, committed enterprises have predictable procurement volume and rapid repayment mechanism, etc., are the driving force behind the reduction of prices.
china's acute myocardial infarction treatment is seriously inadequate data show that the number of cases of coronary heart disease intervention in China more than 1 million cases, coronary stent use of more than 1.6 million.
experts said that China's acute myocardial infarction treatment is still seriously inadequate.
coronary stent, also known as the heart stent, is a commonly used medical device in coronary artery intervention therapy (PCI).
, china's demand for coronary braces is in the rapid release stage.
2015-2019, the number of PCI surgery cases in China increased from 568,000 to 1.098 million, with a compound annual growth rate of 17.9%, according to the data.
is understood that China has an average of 542 cases of coronary artery intervention per 1 million people, compared with more than 2,000 cases per 1 million people in Japan and more than 3,000 cases in the United States during the same period.
, it can be Chinese the number of coronary coronary artery interventional procedures is still at a low level compared with developed countries.
National Health Commission cardiovascular intervention management expert group leader Ho Yong: Especially in China's acute myocardial infarction treatment is seriously inadequate, because acute myocardial infarction coronary intervention therapy, that is, put stents, is one of the most effective means to reduce patient death.
only about 10% of patients with acute myocardial infarction did this treatment.
, especially these patients, a considerable number of patients, have not been able to do such treatment in a timely manner.
so China's coronary heart disease interventional treatment, the future development is still very big.
。